Genetics and epigenetics of 1q rearrangements in hematological malignancies

Cytogenetic and Genome Research

Volumn 118, Issue 2-4, 2007, Pages 320-327

  Fournier, A ^a   Florin, A ^a   Lefebvre, C ^a,b   Solly, F ^a,b   Leroux, D ^a,b   Callanan, M B ^a,b  

^a INSTITUT ALBERT BONNIOT   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

B LYMPHOCYTE; CANCER INHIBITION; CELL AGING; CELL STRESS; CHROMOSOME 1Q; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETICS; HETEROCHROMATIN; HUMAN; INTROSPECTION; LYMPHOMA CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ONCOGENE; PATHOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 36248940821     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108316     Document Type: Review

References (84)

1. Alcobia I, Dilao R, Parreira L: Spatial associations of centromeres in the nuclei of hematopoietic cells: evidence for cell-type-specific organizational patterns. Blood 95:1608-1615 (2000).
2. Alcobia I, Quina AS, Neves H, Clode N, Parreira L: The spatial organization of centromeric heterochromatin during normal human lymphopoiesis: evidence for ontogenically determined spatial patterns. Exp Cell Res 290:358-369 (2003).
3. Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, et al: Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 140:118-123. (2003).
4. Andrulis ED, Neiman AM, Zappulla DC, Sternglanz R: Perinuclear localization of chromatin facilitates transcriptional silencing. Nature 394:592-595 (1998). Erratum, Nature 395:525 (1998).
5. Avet-Loiseau H, Vigier M, Moreau A, Mellerin MP, Gaillard F, et al: Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas. Br J Haematol 97:119-122 (1997).
6. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, et al: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495 (2007).
7. Barki-Celli L, Lefebvre C, Le Baccon P, Nadeau G, Bonnefoix T, et al: Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements. Genes Chromosomes Cancer 43:339-349 (2005).
8. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030 (2006).
9. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, et al: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190 (2005).
10. Bernstein E, Allis CD: RNA meets chromatin. Genes Dev 19:1635-1655 (2005).
11. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, et al: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436:660-665 (2005).
12. Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, et al: Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. Cell 91:845-854 (1997).
13. Brown KE, Baxter J, Graf D, Merkenschlager M, Fisher AG: Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division. Mol Cell 3:207-217 (1999).
14. Busson-Le Coniat M, Salomon-Nguyen F, Dastugue N, Maarek O, Lafage-Pochitaloff M, et al: Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations. Leukemia 13:1975-1981 (1999).
15. Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355:2452-2466 (2006).
16. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, et al: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325 (2006).
17. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, et al: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-1256 (2004).
18. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, et al: Molecular dissection of hyper-diploid multiple myeloma by gene expression profiling. Cancer Res 67:2982-2989 (2007).
19. Chubb JR, Bickmore WA: Considering nuclear compartmentalization in the light of nuclear dynamics. Cell 112:403-406 (2003).
20. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, et al: Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 91:3007-3010 (1998).
21. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, et al: Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 178:3307-3315 (2007).
22. Cremer M, Kupper K, Wagler B, Wizelman L, von Hase J, et al: Inheritance of gene density-related higher order chromatin arrangements in normal and tumor cell nuclei. J Cell Biol 162:809-820 (2003).
23. Cremer T, Cremer C: Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat Rev Genet 2:292-301 (2001).
24. Croft JA, Bridger JM, Boyle S, Perry P, Teague P, et al: Differences in the localization and morphology of chromosomes in the human nucleus. J Cell Biol 145:1119-1131 (1999).
25. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442 (2006).
26. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, et al: Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia 21:1113-1116 (2007).
27. Fandy TE, Carraway H, Gore SD: DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 13:40-48 (2007).
28. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33 (2006).
29. Fischle W, Wang Y, Allis CD: Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172-183 (2003).
30. Fisher AG, Merkenschlager M: Gene silencing, cell fate and nuclear organisation. Curr Opin Genet Dev 12:193-197 (2002).
31. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, et al: Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546-1558 (2004).
32. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400 (2005).
33. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, et al: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38:540-549 (2006).
34. Govin J, Caron C, Rousseaux S, Khochbin S: Testis-specific histone H3 expression in somatic cells. Trends Biochem Sci 30:357-359 (2005).
35. Grewal SI, Jia S: Heterochromatin revisited. Nat Rev Genet 8:35-46 (2007).
36. Grogan JL, Mohrs M, Harmon B, Lacy DA, Sedat JW, et al: Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14:205-215 (2001).
37. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, et al: Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 104:2661-2666 (2004).
38. Hake SB, Allis CD: Histone H3 variants and their potential role in indexing mammalian genomes: the 'H3 barcode hypothesis'. Proc Natl Acad Sci USA 103:6428-6435 (2006).
39. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, et al: Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732 (2006).
40. Hattinger CM, Potschger U, Tarkkanen M, Squire J, Zielenska M, et al: Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 86:1763-1769 (2002).
41. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430 (2006).
42. Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, et al: Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35:318-328 (2002).
43. Kosak ST, Skok JA, Medina KL, Riblet R, Le Beau MM, et al: Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science 296:158-162 (2002).
44. Kuppers R, Klein U, Hansmann ML, Rajewsky K: Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520-1529 (1999).
45. Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, et al: Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 32:250-264 (2001).
46. Liebisch P, Wendl C, Wellmann A, Krober A, Schilling G, et al: High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 17:2535-2537 (2003).
47. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, et al: Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 360:385-386 (2002).
48. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev 18:2315-2335 (2004).
49. Mellor J: It takes a PHD to read the histone code. Cell 126:22-24 (2006).
50. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, et al: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070-2079 (2006).
51. Metz A, Soret J, Vourc'h C, Tazi J, Jolly C: A key role for stress-induced satellite III transcripts in the relocalization of splicing factors into nuclear stress granules. J Cell Sci 117:4551-4558 (2004).
52. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, et al: CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194-4197 (2006).
53. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, et al: Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703-716 (2003).
54. Nightingale KP, O'Neill LP, Turner BM: Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 16:125-136 (2006).
55. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 3:189-201 (1991).
56. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, et al: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107:4500-4507 (2006).
57. Parker MJ, Licence S, Erlandsson L, Galler GR, Chakalova L, et al: The pre-B-cell receptor induces silencing of VpreB and lambda5 transcription. EMBO J 24:3895-3905 (2005).
58. Rosinol L, Carrio A, Blade J, Queralt R, Aymerich M, et al: Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 130:729-732 (2005).
59. Ryan RF, Schultz DC, Ayyanathan K, Singh PB, Friedman JR, et al: KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol Cell Biol 19:4366-4378 (1999).
60. Sambani C, La Starza R, Pierini V, Vandenberghe P, Gonzales-Aguilera JJ, et al: Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genet Cytogenet 162:45-49 (2005).
61. Saurin AJ, Shiels C, Williamson J, Satijn DP, Otte AP, et al: The human polycomb group complex associates with pericentromeric heterochromatin to form a novel nuclear domain. J Cell Biol 142:887-898 (1998).
62. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B: Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91:1732-1741 (1998).
63. Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, et al: Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 42:95-106 (2005).
64. Sewalt RG, Lachner M, Vargas M, Hamer KM, den Blaauwen JL, et al: Selective interactions between vertebrate polycomb homologs and the SUV39H1 histone lysine methyltransferase suggest that histone H3-K9 methylation contributes to chromosomal targeting of Polycomb group proteins. Mol Cell Biol 22:5539-5553 (2002).
65. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, et al: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276-2284 (2006).
66. Shi S, Calhoun HC, Xia F, Li J, Le L, et al: JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 38:1071-1076 (2006).
67. Spector DL: The dynamics of chromosome organization and gene regulation. Annu Rev Biochem 72:573-608 (2003).
68. Stange DE, Radlwimmer B, Schubert F, Traub F, Pich A, et al: High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 12:345-352 (2006).
69. Staudt LM: Molecular diagnosis of the hematologic cancers. N Engl J Med 348:1777-1785 (2003).
70. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 403:41-45 (2000).
71. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, et al: Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38:1386-1396 (2006).
72. Su RC, Brown KE, Saaber S, Fisher AG, Merkenschlager M, et al: Dynamic assembly of silent chromatin during thymocyte maturation. Nat Genet 36:502-506 (2004).
73. Taddei A, Roche D, Bickmore WA, Almouzni G: The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6:520-524 (2005).
74. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, et al: Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106:1770-1777 (2005).
75. Talbert PB, Henikoff S: Spreading of silent chromatin: inaction at a distance. Nat Rev Genet 7:793-803 (2006).
76. Tanabe H, Muller S, Neusser M, von Hase J, Calcagno E, et al: Evolutionary conservation of chromosome territory arrangements in cell nuclei from higher primates. Proc Natl Acad Sci USA 99:4424-4429 (2002).
77. Tomlinson GE, Douglass EC, Pollock BH, Finegold MJ, Schneider NR: Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 44:177-184 (2005).
78. Turner BM: Cellular memory and the histone code. Cell 111:285-291 (2002).
79. van Dekken H, Wink JC, Vissers KJ, van Marion R, Koppert LB, et al: Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: tumor progression is associated with alteration of 1q and 8p sequences. Genes Chromosomes Cancer 45:516-525 (2006).
80. Vourc'h C, Taruscio D, Boyle AL, Ward DC: Cell cycle-dependent distribution of telomeres, centromeres, and chromosome-specific subsatellite domains in the interphase nucleus of mouse lymphocytes. Exp Cell Res 205:142-151 (1993).
81. Walter J, Schermelleh L, Cremer M, Tashiro S, Cremer T: Chromosome order in HeLa cells changes during mitosis and early G1, but is stably maintained during subsequent interphase stages. J Cell Biol 160:685-697 (2003).
82. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al: The molecular classification of multiple myeloma. Blood 108:2020-2028 (2006a).
83. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, et al: A gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109:1692-1700 (2006b).
84. Zudaire I, Odero MD, Caballero C, Valenti C, Martinez-Penuela JM, et al: Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 40:547-555 (2002).